EP1782829A1 — Preventive and/or remedy for hyperkalemia containing ep4 agonist
Assigned to Ono Pharmaceutical Co Ltd · Expires 2007-05-09 · 19y expired
What this patent protects
The present invention relates to a preventive and/or therapeutic agent for hyperkalemia, and a potassium excretion promoter containing EP 4 agonist. Since EP 4 agonist promotes potassium excretion, it is useful as a preventive and/or therapeutic agent for hyperkalemia. In addit…
USPTO Abstract
The present invention relates to a preventive and/or therapeutic agent for hyperkalemia, and a potassium excretion promoter containing EP 4 agonist. Since EP 4 agonist promotes potassium excretion, it is useful as a preventive and/or therapeutic agent for hyperkalemia. In addition, if selective EP 4 agonist uses, it is a preventive and/or therapeutic agent for hyperkalemia without side effects. Further, if EP 4 agonist is used, it is useful as improving agent for various symptoms (e.g. paresthesia, error of perception, weakness, myoparalysis, nausea, vomit, abdominal pain, diarrhea, arrhythmia, atrioventricular block, ventricular fibrillation, atrial fibrillation, cardiac arrest, asphyxia and/or dyspnoea etc .).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.